Wheatley-Price Paul, Shepherd Frances A
University Health Network, Princess Margaret Hospital Division and the University of Toronto, Toronto, Ontario, Canada.
Curr Opin Oncol. 2008 Mar;20(2):162-75. doi: 10.1097/CCO.0b013e3282f335a3.
Inhibition of the epidermal growth factor receptor (EGFR) is now an established part of the treatment of nonsmall cell lung cancer. This review summarizes the clinical trials that have been performed with monoclonal antibodies and small molecule tyrosine kinase inhibitors targeting EGFR in nonsmall cell lung cancer.
Erlotinib has established second and third-line efficacy following the BR.21 study. Recently the INTEREST trial showed gefitinib to have an equivalent outcome to docetaxel in the second line setting. Numerous other tyrosine kinase inhibitor drugs and monoclonal antibodies have demonstrated clinical activity in phase I and phase II trials. Novel tyrosine kinase inhibitors may have the ability to overcome resistance to first generation tyrosine kinase inhibitor therapy. Furthermore there are encouraging studies combining EGFR inhibitors and antiangiogenesis drugs such as bevacizumab.
EGFR inhibition, by a range of strategies, remains a central node in the treatment of nonsmall cell lung cancer.
抑制表皮生长因子受体（EGFR）现已成为非小细胞肺癌治疗的既定组成部分。本综述总结了针对非小细胞肺癌中EGFR的单克隆抗体和小分子酪氨酸激酶抑制剂所进行的临床试验。
厄洛替尼在BR.21研究后确立了二线和三线治疗的疗效。最近，INTEREST试验表明吉非替尼在二线治疗中与多西他赛疗效相当。许多其他酪氨酸激酶抑制剂药物和单克隆抗体在I期和II期试验中已显示出临床活性。新型酪氨酸激酶抑制剂可能有能力克服对第一代酪氨酸激酶抑制剂治疗的耐药性。此外，将EGFR抑制剂与抗血管生成药物如贝伐单抗联合使用的研究也令人鼓舞。
通过一系列策略抑制EGFR仍然是非小细胞肺癌治疗的核心环节。
Zotero 插件